Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Pharmacokinetic/pharmacodynamic (PK/PD) exposure-response characterization of GSK3359609 (GSK609) from INDUCE-1, a phase I open-label study

Date

02 Mar 2020

Session

Poster Display & Cocktail

Presenters

Eric Angevin

Citation

Annals of Oncology (2020) 31 (suppl_1): S1-S7. 10.1016/annonc/annonc86

Authors

E. Angevin1, S. Groenland2, T. Bauer3, D. Rischin4, I. Gardeazabal5, V. Moreno6, J.M. Trigo7, M. Chisamore8, J. Shaik9, F. Rigat10, C. Ellis9, H. Chen9, R. Gagnon9, S.J. Scherer9, D. Turner9, S. Yadavilli9, M. Ballas9, A. Hoos9, M. Maio11

Author affiliations

  • 1 Gustave Roussy Institut de Cancérologie, 94805 - Villejuif/FR
  • 2 Antoni van Leeuwenhoek, Netherlands Cancer Institute, Amsterdam/NL
  • 3 Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville/US
  • 4 Peter MacCallum Cancer Centre and the University of Melbourne, Melbourne/AU
  • 5 Hospital Universitario "Marqués de Valdecilla", Santander/ES
  • 6 START Madrid-FJD, University Hospital "Fundacion Jimenez Diaz", Madrid/ES
  • 7 Hospital Universitario Virgen de la Victoria, Málaga/ES
  • 8 Merck & Co., Inc, North Wales/US
  • 9 GSK, Collegeville/US
  • 10 GSK, Stevenage/GB
  • 11 University Hospital of Siena, Siena/IT
More

Resources

GSK609 an agonist IgG4 monoclonal antibody (mAb) against inducible co-stimulatory receptor (ICOS) exhibits T cell mediated immune stimulating and anti-tumor activity. INDUCE-1 is the first in human study investigating GSK609 alone and in combinations which include pembrolizumab in select tumor types including recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings